AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Ranbaxy obtains approval to market malaria drug in India

 INDIA  Comments Off on Ranbaxy obtains approval to market malaria drug in India
Oct 232013
 

Ranbaxy Laboratories has secured approval from India’s Central Drugs Standard Control Organisation (CDSCO) to produce and market its Synriam drug in the country to treat malaria caused by the Plasmodium vivax parasite in adults.

Ranbaxy obtains approval to market malaria drug in India  CLICK HERE

http://www.pharmaceutical-technology.com/news/newsranbaxy-obtains-approval-market-malaria-drug-india?WT.mc_id=DN_News

Share

DCGI asks Wockhardt, Ranbaxy to explain lapses

 companies  Comments Off on DCGI asks Wockhardt, Ranbaxy to explain lapses
Sep 022013
 

the-drug-regulator-is-now-awaiting-responses-from-the-companies-to-take-further-action

Indian drug makers Ranbaxy and Wockhardt have been issued a letter by the DCGI to explain deficiencies found at the company’s manufacturing units

Following an import alert by the US FDA, Indian drug maker Wockhardt has now been asked to explain the lapses at the company’s Aurangabad based manufacturing unit that was pulled up by the US drug regulator earlier this year Indian drug makers Ranbaxy and Wockhardt have been issued a letter by the DCGI to explain deficiencies found at the company’s manufacturing units
The Indian Drug Controller General of India (DCGI) has written a letter to the drug maker Wockhardt to explain the deficiencies found at its Aurangabad manufacturing unit. The FDA had issued an import alert to the drug maker earlier this year.
Read more at: http://www.biospectrumasia.com/biospectrum/regulatory/194552/dcgi-wockhardt-ranbaxy-explain-lapses#.UiQ6X6I3CSo

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: